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Introduction
Sjögren’s syndrome (SS) is a chronic systemic auto-
immune disease mainly aﬀ  ecting the exocrine glands. For 
this reason, the deﬁ  nition of autoimmune exocrinopathy 
has been proposed in the past for this disorder [1]. 
Behind the involvement of exocrine glands (pre-
dominantly the lachrymal and the salivary glands), other 
nonexocrine epithelial lesions may be observed in a large 
number of patients. Consequently, the disease has been 
alternatively termed as autoimmune epithelitis [2]. 
Finally, auto  anti  body-mediated or immune-complex-
mediated vasculitic lesions – compromising various 
organs or systems, such as the peripheral or central 
nervous system, skin, lung or kidney – may complicate 
the disease course, in a more limited number of patients. 
Th  is justiﬁ   es the inclusion of SS among the systemic 
autoimmune diseases [3]. Furthermore, SS has received 
the attribute primary (pSS) when it appears alone, or 
secondary when it is associated with another well-deﬁ  ned 
systemic autoimmune disease, such as systemic lupus, 
rheumatoid arthritis or systemic sclerosis [4].
Th  e presence of focal lymphomonocytic inﬁ  ltrates in 
the target organs, particularly in the salivary and lachry-
mal glands, has been considered the hallmark of the 
disease. Th   e focus consists of an agglomerate of inﬂ  am-
matory cells, mainly lymphocytes, which are located 
around the acinar and ductal structures of the glands. 
Th  e presence of at least 50 mononuclear cells is the 
conventionally accepted deﬁ   nition for the focus [5]. 
Because of the diﬃ     culty in obtaining lachrymal gland 
tissue, and the fear of causing facial nerve palsy or parotid 
ﬁ   stulae in performing parotid gland biopsy, obtaining 
glandular tissue from minor salivary glands (MSGs) has 
been proposed as a more easily and less invasive 
approach for the histologic analysis of the target tissue 
[5]. Th   e biopsy of sublingual glands has been alternatively 
suggested, but it seems to be a more complicated surgical 
way to take a sample of gland salivary tissue [6]. However, 
the existence of some important diﬀ  erences between the 
histological features found in major and minor salivary 
glands has been pointed out in several studies, and the 
biopsy of the parotid has been recently re-evaluated as an 
easy and safe method of obtaining salivary tissue [7].
A suﬃ     cient number of gland lobuli for histological 
exami  nation can be obtained without any particular 
diﬃ   culty by performing a MSG biopsy on the lower lip. A 
permanent, although limited, sensory loss of the mucosa 
of the lower lip – occurring in a minority of patients – is 
the only known complication of a labial biopsy [7]. 
Several authors also proposed diﬀ  erent scoring systems 
of focal inﬁ   ltrates observed in MSGs, and also the 
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Moreover, some authors proposed that the presence of a 
given focal score in MSGs could be the mandatory 
criterion to classify a patient as having SS [5]. Th  is  point 
has been debated for a long time by the scientiﬁ  c 
community. Th   e American–European Consensus Criteria 
for the classiﬁ  cation of SS ﬁ  nally established that, among 
the six items composing the criteria set, either focal 
sialoadenitis at MSG biopsy (with a focus score >1 for 
4  mm2 glandular tissue) or the presence of speciﬁ  c 
autoantibodies should be mandatory for the diagnosis of 
pSS [10].
Salivary glands (and also lachrymal glands) are not the 
exclusive inﬂ  ammatory targets for SS. Sicca features may 
be part of the clinical picture of other disorders, in which 
a focal sialoadenitis, with histological characteristics 
evocative of SS, can be found [11]. Besides sarcoidosis, 
where a focal granulomatosous sialoadenitis has been 
described, and the histological examination of MSGs can 
be useful in some cases to deﬁ  ne diagnosis [12], even 
hepatitis C virus (HCV) [13] and HIV [14] infections may 
exhibit, in diﬀ   erent phases of the disease, sicca 
complaints, with the histological counterpart of a focal 
sialoadenitis. Th   is induced the American–European 
Consensus Group for the Classiﬁ    cation of SS to list HCV 
and HIV infections among the exclusion criteria for SS 
[10].
In clinical practice, however, the presence of these 
overlapping features in the various disorders may gener-
ate some diﬃ   culties in the diﬀ  erential diagnostic deﬁ  ni-
tion. Th  ese  diﬃ   culties can certainly be solved, alongside 
the viral investigations, by better deﬁ   ning the patho-
logical diﬀ  erences between the focal sialoadenitis in the 
various conditions, using more sophisticated immuno-
pathological techniques. In addition, the evidence that 
some viral infections may have salivary glands as one of 
the possible localisations, and that focal sialoadenitis may 
be the result of the local pathological process, again 
supports the theory – often proposed, but never com-
pletely proven – that some viral agent(s) could trigger the 
immunopathological cascade in pSS [15].
Immunopathological features of sialadenitis in pSS
Salivary epithelial cells certainly play a crucial role in the 
pathological process of pSS. In an adequate environment 
of stressor agents and hormonal stimulation, and in the 
presence of a speciﬁ   c genetic background, these cells 
probably become susceptible to viral aggression. Diﬀ  er  ent 
viral agents such as Epstein–Barr virus, nonhuman 
immuno deﬁ  ciency retroviruses and, more recently, cox-
sackie  viruses [15,16] have been postulated to be capable 
of triggering pSS. Th   e expression of Toll-like receptor 3 
on salivary glands and epithelial cell lines derived from 
patients aﬀ  ected by pSS may suggest that the engagement 
of epithelial cells by virus may happen via Toll-like 
receptor 3 [17]. Th  e inadequate clearance of these viral 
agents and/or the consequent damage of the epithelial 
cells initiate a cascade of events that may lead to the self-
maintenance of inﬂ  ammatory mechanisms and induction 
of autoimmune manifestations. Th  e insult may induce 
upregulation of type I interferon by epithelial cells and 
plasmacytoid dendritic cells, as demonstrated by IFNγ 
RNA overexpression in salivary gland tissue [18]. Secondly, 
viral injury may induce apoptosis or necrosis of glandular 
epithelial cells, with the consequent release of auto-
antigens, which become available for professional 
antigen-presenting cells [18]. Th   e fact that epithelial cells 
may also work as nonprofessional antigen-presenting 
cells is still under debate [19]. Th   is hypothesis has been 
suggested by the evidence that epithelial cells, when 
activated, may express class I and class II MHC molecules 
on their surface [20], together with co-stimulatory 
molecules [21], and are probably able to engage T cells 
for the presentation of autoantigens once relocated from 
the nucleus to the cellular surface [22]. Finally, epithelial 
cells are certainly important in T-cell recruitment since 
they produce both intracellular and vascular adhesion 
molecules [23] and diﬀ  erent types of chemotactic factors, 
including chemokines.
Once T cells are ﬁ  rst attracted into the glandular tissue, 
they assume the role of the main actors in the inﬂ  am-
matory scene [24], by perpetuating the recruitment of 
other inﬂ  ammatory cells, mainly B cells, by expressing a 
restricted repertoire of T-cell receptors that can recog-
nise autoantigens presented by antigen-presenting cells, 
and by activating macrophages (via the IFNγ signal). Th  ese 
latter cells act as the main agents responsible for further 
salivary tissue injury, mainly by producing TNFα [25].
Th  e great importance of T cells in the immmuno-
pathological scenario of pSS is strongly conﬁ  rmed by the 
common observation that focal lymphocytic inﬁ  ltrates 
are mainly constituted of T cells with a large pre  domi-
nance of CD4+ with respect to the CD8+ T cells (CD4/
CD8 ratio ranging from 3:1 to 5:1) [24]. B cells represent 
approximately 20% of the inﬁ  ltrating cell population at 
least in some stages of disease [24]. In addition, macro-
phages, natural killer cells and dendritic cells are 
observed in more limited numbers [26]. More recent 
studies have also shown that two other diﬀ  erent T-cell 
subpopulations are represented in the salivary gland 
inﬁ  ltrates. Th  17 cells are a distinct CD4+ T-helper cell 
population expressing IL-17 that are strongly implicated 
in autoimmune diseases. Increased plasma levels of IL-17 
have been observed in SS, and Th  17 cells seem to be 
signiﬁ  cantly represented in MSG inﬁ  ltrates [27]. Trans-
forming growth factor beta (TGFβ), IL-23 and IL-6 are 
the main promoters of the Th  17 diﬀ  erentiation  and 
proliferation [27]. TGFβ is also the pivotal diﬀ  eren  tiation 
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an immunosuppressive role in the chronic immuno-
pathologic process [28]. T-regulatory cells have also been 
found in variable proportions in salivary biopsy 
specimens of patients with pSS [29].
Recent investigations have shown that the inﬂ  amma-
tory cell presence, proportion and organisation may 
greatly vary in the disease course, and in various subsets 
of patients, according to disease severity and evolution 
[30]. CD4+ T cells predominate in mild sialoadenitis and 
seem to be associated with the presence of a clinically 
signiﬁ   cant articular involvement. Th  e B-cell presence 
pro  gressively grows from intermediate to severe histo-
logical lesions. Th   e predominance of B cells in inﬁ  ltrates 
and their organisation in the germinal-centre-like struc-
ture is strongly associated with hypergamma  globu  lin-
aemia, hypocomplementaemia, rheumatoid factor and 
autoantibody production, and, from a clinical point of 
view, with salivary gland swelling, vasculitic manifes-
tations and lymphoproliferation [30]. Foxp3+ T-regu  la-
tory cells are mainly represented in the intermediate 
grade of lymphocytic inﬁ  ltration and decline in severe 
histological lesions [29,30]. On the contrary, macro-
phages are more abundant in severe lesions, as well as 
dendritic cells. Th  ese latter cells are largely represented 
in more advanced lesions [26,30], and particularly in the 
germinal-centre-like structure, where they appear to 
form a network that is essential for the organisation of 
the inﬁ  ltrates [30,31]. Finally, IL-17 protein expression 
progressively increases with a higher focus score, 
indicating an expansion of the Th  17 subpopulation in 
more severe phases of the disease [30].
Th   e passage from a predominance of CD4+ cells to that 
of B lymphocytes in glandular inﬁ  ltrates is therefore charac-
teristic of a more advanced severe disease pattern, which is 
correlated with systemic manifestations and higher risk of 
developing lymphoproliferative disorders [32].
B lymphocytes in salivary gland inﬁ  ltrates in SS are 
mainly represented by polyclonal CD27+ memory B cells 
[33]. Homing of this kind of B cell seems to predominate 
with respect to local proliferation of a few founder B cells 
[33]. A large number of chemokines may all contribute to 
B-lymphocyte homing and chronic maintenance. A 
particular proﬁ  le of chemokines, however, is predomi-
nantly active in SS. Th  is proﬁ   le is represented by the 
CXCL13 and CXCL12 chemokines, which speciﬁ  cally 
attract CD27+ memory B cells expressing the correspond-
ing receptors (CXCR4 and CXCR5) [33]. Recent data 
have shown a large expression of these receptors in the 
glandular inﬁ  ltrates of patients with SS. Th  e interaction 
of B cells attracting chemokines with their speciﬁ  c recep-
tors has been suggested to be essential for B-cell recruit-
ment and organisation in a tertiary germinal-centre-like 
structure [34].
Behind memory B cells there is a convincing 
demonstration of the contemporary presence of marginal 
zone (MZ)-like B cells within the lymphoid inﬁ  ltrates in 
SS [35]. Th  ese MZ-like B cells may work as reactive B 
cells against locally expressed autoantigens. Because of 
the permanent availability of autoantigens, the continu-
ous stimulation of these autoreactive cells leads to the 
evolution from polyclonal to oligoclonal and then 
monoclonal selection, and ﬁ  nally to the development of 
mucosa-associated lymphoid tissue (MALT) B-cell 
lymphoma [35].
B-cell recruitment, survival, proliferation and organisa-
tion are strongly inﬂ  uenced in SS by the large production 
of B-cell activating factor (BAFF) and a proliferation-
inducing ligand (APRIL) [33,35]. In particular, enhanced 
levels of BAFF have been shown in most of the systemic 
autoimmune diseases, usually associated with B-cell 
hyperactivity. Th   e highest plasma BAFF levels, however, 
have been found in patients with SS, and a strong local 
overexpression of this substance has been demonstrated 
in salivary gland inﬁ  ltrates [36], particularly in patients 
with a high focus score. BAFF is produced locally by 
diﬀ  erent cell types, including dendritic cells, T lympho-
cytes and macrophages, and certainly plays an important 
role in local B-cell proliferation, including that of MZ-like 
B-cell, germinal-centre-like formation, autoantibody 
produc  tion and probably B-cell lymphomagenesis [37].
Immunopathological features of sialadenitis in 
chronic HCV infection
Besides hepatocytes and lymphocytes, HCV seems to 
have a special tropism for lachrymal and salivary 
epithelial cells. HCV RNA has been found both in saliva 
and salivary gland tissue [38], and in situ hybridisation 
studies have clearly demonstrated that HCV is exclusively 
localised in the salivary epithelial cell cytoplasma [39]. A 
chronic focal sialoadenitis, resembling that of SS, can be 
observed in approximately 50% of HCV-infected patients, 
while signs of mild inﬂ  ammatory inﬁ  ltration are present 
in a greater proportion of patients [40]. Sicca symptoms, 
however, seem to be less frequent and milder in HCV-
infected patients. Th  ese ﬁ  ndings have stimulated a long 
debate on the possibility that HCV could be considered 
at least one of the candidate viruses to work as trigger 
agents for pSS. Th  is hypothesis has been supported by 
several papers in which HCV infection appeared to be 
more prevalent in patients with pSS than in healthy 
controls (reviewed in [41]). Other data, however, have 
shown that the prevalence of HCV infection in patients 
with deﬁ   ned pSS was similar to that observed in the 
normal population, and that the overestimation pre  viously 
reported could by ascribed to diﬀ  erent  classiﬁ    cation 
criteria used in diﬀ  erent studies, and to hyper  gamma-
globulinaemia frequently present in the sera of patients 
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infection and deﬁ  ned pSS (and lymphoma) in the same 
patients has been sporadically reported, and the 
demonstration that this association can be ascribed to 
chance alone is still under discussion [43]. According to 
the American–European Consensus Criteria, however, 
evidence of HCV infection is an exclusion criterion for 
the classiﬁ  cation of a patient as having SS [10].
Th   e amount of information available on the charac  ter-
istics of the focal inﬁ  ltrates in salivary glands of HCV-
infected patients is not as extensive as that accumulated 
in SS. Th  is is undoubtedly due to the greater attention 
devoted to the predominance of liver involvement in 
HCV infection, and to the fact that features diﬀ  erent 
from sicca complaints are more clinically signiﬁ  cant in 
HCV infection with extra-hepatic manifestations. 
Histologic examination of salivary glands in HCV-
infected patients shows diﬀ  erent aspects with respect to 
those found in SS patients. Lymphocytic inﬁ  ltrates often 
may be located in the pericapillary area rather than 
around the glandular ducts. In addition, a lack of damage 
(or mild damage) of the glandular tissue has also been 
reported [41,44]. Th   e lymphocytic subpopulations 
present in glandular inﬁ   ltrates appear to be diﬀ  erent, 
sometimes being represented by a predominance of CD8+ 
T lymphocytes, at least in some areas. More commonly, 
CD4+ T cells constitute the most represented population 
in the inﬁ  ltrates. However, even in this latter case, the 
CD4/CD8 ratio is usually lower than that observed in SS 
patients with pSS [44]. Th   ere is no demonstration of any 
translocation and expression of autoantigen peptides in 
salivary gland epithelial cells, and therefore the corres-
ponding autoantibodies are not detectable in the sera of 
HCV-infected patients [45]. On the contrary, serum 
cryoglobulins and hypocomplement  aemia are usually 
found in a large proportion of HCV-infected patients, and 
are considered markers or pre  dic  tors for the develop  ment 
of extra-hepatic manifestations of the disease, such as 
cutaneous vasculitis (cryo  globulin  aemic purpura), peri-
pheral neuropathy, glomerulo nephritis and sicca syndrome 
[45].
Th  e pathogenetic mechanism underlying focal sialo-
adenitis in HCV-infected patients has not so far been 
clariﬁ   ed. Transgenic mice carrying the HCV envelope 
genes for E1 and E2 proteins developed an exocrinopathy 
involving salivary and lachrymal glands [46]. Th  is study 
clearly indicates a direct role for these viral proteins in 
the pathogenesis of HCV-related sialoadenitis. Molecular 
mimicry between HCV-E2 protein and an antigenic 
protein present in exocrine epithelial cells has been 
suggested as a potential autoimmune mechanism induc-
ing lymphocyte homing and activation [47]. On the other 
hand, one could simply speculate that the HCV infection 
of the salivary epithelial cells may be the initial event that 
is suﬃ   cient to induce the activation of innate immunity 
with the consequent production of proinﬂ  ammatory cyto-
kines, such as INFγ and IL-2, in a way similar to that 
demon  strated to occur in HCV-infected hepatocytes [48].
Lymphomagenesis in Sjögren’s syndrome and HCV 
chronic infection
Besides sharing similar clinical and serological features, 
such as cutaneous vasculitis, peripheral neuropathy and
hypocomplementaemia, either patients with chronic 
HCV infection associated with mixed cryoglobuli-
naemia or patients with pSS may develop B-cell lym-
phomas with a higher prevalence than in the normal 
population [43]. Th  e most common type of B-cell 
lymphoma in both disorders is a MZ low-grade 
lymphoma, where the pro  liferating cells are rheumatoid 
factor-positive auto  reactive B cells [43]. A signiﬁ  cant 
proportion of HCV-infected patients may also develop 
diﬀ  use large B-cell lymphoma, probably by completely 
diﬀ   erent patho  genetic mechanisms [49]. In both 
diseases the low-grade B-cell lymphoma develop  ment 
represents a pathological model of an antigen-driven 
expansion from polyclonal/oligoclonal to mono  clonal 
proliferation of B cells [50]. Th  e process is probably 
driven by autoantigen(s) in SS [43] and by viral 
antigen(s) in HCV infection [50]. Th  e fact that the 
process of low-grade B-cell lymphoma develop  ment is 
similar in both conditions is also supported by mole-
cular studies demon  strating a similar restricted usage of 
genes encoding for heavy and light variable regions and 
similar somatic mutations of the comple  mentary-
determining region of the surface antigen receptor in 
monoclonal B cells from patients with SS and HCV-
related mixed cryoglobulinaemia [51].
Th   e site of development of these B-cell lymphomas is 
typically extra-nodal, since the salivary gland is the 
preferential site for lymphomas that appear in the course 
of SS, and the liver and salivary gland are the preferential 
sites for lymphomas developing in HCV-infected patients 
with associated sicca complaints [52]. In both conditions, 
a possible evolution to diﬀ  use large-cell lymphoma has 
been reported [52].
Clonality studies revealing monoclonal B-cell expan  sion 
in target tissues of both conditions are not strictly 
indicative of lymphoma [53]. Th   ese clones may disappear 
after antiviral therapy in HCV-infected patients [54], or 
may persist in the same site for a long time without 
evolving to frank lymphoma. Clonality studies are 
therefore certainly useful at least to predict possible 
development of a frank lymphoma.
Sialoadenitis in HIV-infected patients
HIV-infected individuals are at an increased risk of 
developing associated rheumatic diseases [55]. Before the 
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(HAART), retrospective studies calculated the rates of 
rheumatic manifestations from 11 to 72% [56]. After the 
HAART implementation, rheumatic complications 
declined signiﬁ  cantly, with some change in the pattern of 
the incidental diseases [57].
A SS-like clinical picture may be present in HIV-
infected patients who develop diﬀ  use  inﬁ  ltrative 
lymphocytosis syndrome (DILS). DILS may be present in 
3 to 50% of HIV-infected populations [58]. Th  is great 
variability between the studies can be ascribed to ethnic 
diﬀ  erences, to the diﬀ  erent criteria used to deﬁ  ne the 
diagnosis (clinical vs. histological) and, ﬁ   nally, to the 
availability of eﬀ  ective antiviral therapy in the various 
populations described in the studies. Recent data strongly 
indicate that, similar to what has been reported for other 
rheumatic manifestations in HIV infection, the preva-
lence of DILS has also been remarkably reduced with the 
introduction of HAART therapy [59]. DILS may mimic 
pSS because DILS also presents with bilateral painless 
parotid gland enlargement, lachrymal gland enlargement 
and sicca symptoms [58]. DILS is characterised by 
circulating CD8+ T cells. Th   e proliferation of CD8+ T cells 
is probably an antigen-driven process and leads to 
inﬁ  ltration of multiple organs, and probably reﬂ  ects an 
excessive host response to HIV [60]. Th  e condition 
usually manifests several years after HIV seroconversion 
and, besides the lymphocitic inﬁ  ltration of salivary and 
lachrymal glands, is characterised by lymphocytic inter-
stitial pneumonitis (31%), myositis (26%) and hepatitis 
(23%) [61]. DILS diﬀ  ers from pSS by the fact that the 
occurrence of extra-glandular involvement is more fre-
quent, whilst the presence of autoantibodies and rheuma-
toid factor is observed in a lower number of patients In 
addition, the two conditions diﬀ   er in the nature of 
inﬁ   ltrating lympho  cytes (CD4+ T cells in pSS, CD8+ 
T cells in DILS) and in the association with diﬀ  erent HLA 
haplotypes [58-60].
Interestingly, some cases of MZ indolent MALT 
lymphomas have rarely been reported in HIV-infected 
patients [62-64], among the large variety of incidental 
malignancies described in the course of the disease [65]. 
MALT lymphoma remission was obtained in these cases 
after HAART, in a way similar to that observed in HCV-
related and Helicobacter pylori-related MALT lymphoma 
after speciﬁ  c antiviral and antibiotic therapies [50]. Th  is 
observa  tion again suggests that infection-related lympho-
mas derived from MZ B cells may share common 
antigen-driven mechanisms [50].
Conclusion
Sicca symptoms and focal sialoadenitis are not exclusive 
features of pSS, but other diseases may present with 
involvement of salivary and lachrymal glands and a 
histological picture of focal inﬁ   ltration in the target 
tissues. Beyond viral serology, which may allow one to 
easily conﬁ  rm the presence of HCV or HIV infection as 
the primary causative agent of the syndrome, other 
clinical, genetic, immunological and histologic ﬁ  ndings 
can help to distinguish pSS from the other SS-like syn-
dromes (Table 1).
Th   e observation that MZ indolent MALT lymphomas 
may develop in all of these conditions has greatly contri-
buted to a more precise understanding of the intriguing 
mechanisms of antigen-driven lympho  pro  liferation.
Table 1. Main clinical, serological, histological, genetic characteristics of focal sialoadenitis
Variable  Primary Sjögren’s syndrome  Hepatitis C virus  HIV-related DILS
Sicca symptoms  Present  Present  Present
Parotid swelling  Moderate to severe  Mild to moderate  Moderate to severe
Extra-glandular manifestations  Mainly pulmonary, gastrointestinal,   Mainly gastrointestinal and musculo-  Mainly musculoskeletal, pulmonary, 
  renal, and neurologic involvement  skeletal involvement  gastrointestinal, and neurologic 
     involvement
Infi  ltrating lymphocytic phenotype  CD4+ T cells  CD4+ T cells  CD8+ T cells
Autoantibodies  High-frequency RF, ANA, anti-Ro/SSA   High frequency of RF   Low-frequency RF, ANA
  and anti-La/SSB  Very low frequency of ANA, 
    anti-Ro/SSA and anti-La/SSB
HLA association  B8, DR2 and DR3  DR-11(DR5)  B45, B49, B50, DR11(DR5), and DRw6
Main characteristics of focal sialoadenitis in primary Sjögren’s syndrome, hepatitis C virus-infected patients and HIV-infected patients developing diff  use infi  ltrative 
lymphocytosis syndrome (DILS). ANA: antinuclear antibodies; RF, rheumatoid factor. Modifi  ed from Basu and colleagues [59].
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